Can you use Wegovy if you have type 1 diabetes?

Is Wegovy licensed or recommended for type 1 diabetes in the UK?

No. The UK licence for Wegovy (semaglutide 2.4 mg, made by Novo Nordisk) is for weight management in adults — it does not extend to type 1 diabetes. NICE's guidance on semaglutide for weight loss, published as Technology Appraisal TA875, sets out the NHS criteria for who qualifies; type 1 diabetes is not among the listed weight-related comorbidities that lower the BMI threshold, and the appraisal's evidence base did not include people with type 1 diabetes.

This matters because type 1 diabetes is a fundamentally different condition from type 2. The body produces no insulin of its own, so glucose management depends entirely on injected or pumped insulin. GLP-1 receptor agonists like semaglutide were developed and trialled in populations with type 2 diabetes or obesity without diabetes. Applying that evidence to a type 1 population is not straightforward, and regulators have not done so.

The NHS medicines page for semaglutide sets out who the medicine is for and what conditions it is used to treat. Type 1 diabetes is not listed as an indication. If you have read something suggesting otherwise (perhaps online, or from a forum) it is worth checking directly against official sources rather than relying on anecdote.

What do we actually know about GLP-1 medicines and type 1 diabetes?

There is genuine scientific interest in whether GLP-1 receptor agonists might benefit people with type 1 diabetes. Small studies and case reports have explored the idea, and some researchers have looked at whether reducing appetite-driven food intake might help stabilise blood glucose swings. That work is ongoing. But interest is not evidence, and research curiosity is not a clinical recommendation.

What the existing literature does flag is a meaningful set of risks. Combining a GLP-1 medicine with insulin can alter insulin requirements significantly, increasing the chance of hypoglycaemia (low blood sugar) if doses are not adjusted carefully. Nausea and reduced appetite, which are common when starting semaglutide, can make carbohydrate counting and bolus dosing less predictable. For someone already walking a careful line with their diabetes management, those disruptions carry real consequences.

There are also questions about diabetic ketoacidosis (DKA) risk in type 1 diabetes, particularly if reduced appetite leads to under-eating without corresponding insulin adjustment. This is the kind of complexity that makes self-initiated treatment through a private weight-loss service genuinely inappropriate for this group. Our overview of semaglutide and type 1 diabetes explores the current research landscape in more detail if you want to read further.

Who should someone with type 1 diabetes speak to about weight management?

Your diabetes specialist team is the only right first port of call. Weight management in type 1 diabetes is a specialist area: the interaction between body composition, insulin sensitivity, carbohydrate intake and glucose control means that standard weight-loss advice (and certainly standard weight-loss medicines) cannot simply be applied without adjustment. Your endocrinologist or diabetes specialist nurse will understand the specific risks involved and can refer you to a dietitian with experience in type 1 diabetes if that is what you need.

If your concern is partly about waiting times or the NHS pathway, it is worth knowing that Wegovy's licensed use in diabetes contexts is strictly within type 2 diabetes, where there is a substantial evidence base and a clear regulatory framework. The broader question of Wegovy for type 2 diabetes is a separate topic with a very different answer.

At nume, our prescribers do not prescribe Wegovy or any other weight-loss medicine to people with type 1 diabetes, it would fall outside the medicine's licence and outside safe clinical practice. Every consultation we conduct involves a GPhC-registered prescriber personally reviewing your medical history, not a set of automated tick-boxes. If type 1 diabetes comes up in that process, the consultation ends there and we will recommend you seek specialist support. That is not a limitation of our service; it is how responsible prescribing works. You can read more about our clinical team and how our prescribers approach these assessments on the clinical team page.

What if you have type 2 diabetes and are also overweight, does the answer change?

Yes, substantially. Wegovy is licensed for weight management in adults with at least one weight-related condition, and type 2 diabetes is specifically included among those conditions in the SmPC and NICE criteria. The evidence base here is robust: the STEP 1 trial, published in the New England Journal of Medicine, demonstrated an average weight reduction of around 15% over 68 weeks in adults with obesity, and type 2 diabetes was among the comorbidities represented in the programme's wider trials.

If you have type 2 diabetes and are wondering whether Wegovy might be suitable, our page on taking Wegovy alongside type 2 diabetes covers the eligibility picture in detail, and if you want a broader look at whether Wegovy is a good option for type 2 diabetes we cover that question separately too. The situation is genuinely different from type 1, and the clinical pathway is clearer. Once your free consultation is complete, a real clinician reviews your answers the same day. If you are approved, your treatment is dispatched promptly, a plain, unbranded box arrives via DPD with tracking so you know exactly when to expect it. It is also worth being aware that if you are pregnant or planning a pregnancy, our page on Wegovy and pregnancy explains what you need to know before starting or continuing treatment. You can check your eligibility to start that process.